By Chris Wack
Roivant Sciences said its subsidiary Kinevant Sciences' phase 2 study of Namilumab failed to show treatment benefit in patients with chronic active pulmonary sarcoidosis.
The phase 2 study showed that Namilumab failed to meet the primary endpoint of proportion of subjects with a rescue event during the double-blind period. Rescue event was defined as clinically significant worsening of a subject's disease requiring treatment, failure to adhere to protocol, or premature discontinuation from the study associated with lack of benefit during the double-blind treatment period.
Pulmonary sarcoidosis is a lung disease characterized by the presence of clumps of immune cells that can cause breathlessness, fatigue and pain.
The study's secondary goals, including change in percent predicted forced vital capacity, corticosteroid tapering success, and change in the patient reported King's Sarcoidosis Questionnaire failed to show a treatment benefit consistent with the primary endpoint.
The safety profile of namilumab in the study was similar to previous studies.
Kinevant will be discontinuing further development of namilumab for the treatment of sarcoidosis, and it will publish the results to inform future sarcoidosis research.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
December 03, 2024 07:35 ET (12:35 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。